Remove tag medicines-optimisation
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). According to Kahn, this results in a need for improved and optimised commercialisation solutions across the industry.

Drugs 147
article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. We have the emergence of this new pillar of medicine, which is out of the lab and beyond clinical trials now. Topic sponsors are not involved in the creation of editorial content.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease

The Pharma Data

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies. Roche’s Chief Medical Officer and Head of Global Product Development.

article thumbnail

CSL doses first patient with haemophilia B gene therapy Hemgenix

Pharmaceutical Technology

The high price tag may be hard to defend , but with lifetime treatment costs for haemophilia B reaching as high as $23m for some, the single-dose treatment could prove far more cost-effective. Despite the limited market, the price tags of haemophilia make it potentially lucrative. Haemophilia B is a rare condition.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Following this, Rebecca Croasdale-Wood, PhD, Director, Augmented Biologics Discovery & Design, Biologics Engineering, Oncology, AstraZeneca, will present: ‘Benchmarking the impact of AI biologics discovery and optimisation for pharma’. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Pietro Sormanni, PhD, Group Leader, Royal Society University Research Fellow, Chemistry of Health, Yusuf Hamied Department of Chemistry, University of Cambridge, on: ‘Third-generation approaches of antibody discovery and optimisation’. The post What to expect from PEGS Europe 2023: Day 3 appeared first on Drug Discovery World (DDW).

Protein 59
article thumbnail

Leveraging flow cytometry in drug discovery 

Drug Discovery World

The main principle involves a well-defined light source such as that produced by lasers that excites fluorescent tags bound to the cells or particles present in a sample. As titrating antibodies can be time-consuming, it is often overlooked from the list of optimisation steps to perform a successful experiment.

Reagent 52